Oncotarget cover image

Oncotarget

Clear Scans Can Be Misleading: Residual Cancer Linked to Worse Outcomes

Mar 20, 2025
Discover the surprising truth about cancer treatment outcomes. Experts reveal that clear scan results can mask hidden cancer, leading to worse long-term effects. They emphasize the need for advanced follow-up techniques, as many patients with clear scans may still harbor microscopic disease. The discussion sheds light on the significant discrepancies between imaging results and tissue analysis, urging a reevaluation of how treatment success is judged. Stay informed about the hidden risks in cancer care that could change survival rates!
03:49

Podcast summary created with Snipd AI

Quick takeaways

  • Residual microscopic cancer cells often remain undetected after stereotactic ablative radiotherapy despite clear scans, leading to worse long-term outcomes.
  • The podcast emphasizes the need for a paradigm shift in assessing treatment success, advocating for more frequent biopsies in cancer follow-up care.

Deep dives

Misleading Clear Scans and Residual Cancer

Radiotherapy, particularly stereotactic ablative radiotherapy (SABR), often shows excellent results in imaging, leading to the misconception that tumors have been eradicated. However, residual microscopic cancer cells can remain undetected, resulting in poorer long-term outcomes for patients. Studies indicate that residual disease is prevalent, with disturbing statistics showing that 40% of lung cancer patients and up to 69% of those with renal cell cancer may still harbor cancer cells despite clear scans. This discrepancy can mislead both clinicians and patients about the true effectiveness of the treatment, as a clean imaging report does not necessarily confirm the complete eradication of cancer.

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner